Abstract
The pathological processes of AD occur in sequence, starting with amyloid beta (Aβ) deposition and progressing into neurodegeneration through neuronal loss and synaptic dysfunction. Great consideration has been given to the sequence of pathologic events in AD, according to which biomarkers reflecting Aβ pathology become positive before those reproducing neuronal degeneration and tangle development. Similarly, trajectories of the Ab42 level in CSF, FDG uptake, and hippocampal volume vary across different cognitive stages. These facts can be used to track the progression of AD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W et al (2011) Characterizing Alzheimer’s disease using a hypometabolic convergence index. Neuroimage 56:52–60
Choo IH, Lee DY, Youn JC, Jhoo JH, Kim KW, Lee DS et al (2007) Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis Assoc Disord 21:77–84
Duara R, Loewenstein DA, Shen Q, Barker W, Varon D, Greig MT et al (2013) The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer’s disease, MCI and cognitively normal elderly subjects. Front Aging Neurosci 5:47
Frankó E, Joly O (2013) Alzheimer’s disease neuroimaging initiative. Evaluating Alzheimer’s disease progression using rate of regional hippocampal atrophy. PLoS One 8:e71354
Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al (2009) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 9:119–128
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL et al (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32:1207–1218
Menéndez-González M, Pérez-Piñera P, Martínez-Rivera M, Muñiz AL, Vega JA (2011) Immunotherapy for Alzheimer’s disease: rational basis in ongoing clinical trials. Curr Pharm Des 17:508–520
Newberg AB, Arnold SE, Wintering N, Rovner BW, Alavi A (2012) Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med 53:902–907
Perneczky R, Hartmann J, Grimmer T, Drzezga A, Kurz A (2007) Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. J Geriatr Psychiatry Neurol 20:84–88
Riverol M, López OL (2011) Biomarkers in Alzheimer’s disease. Front Neurol 2:46
Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ et al (2011) The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol 68:1040–1048
Tarawneh R, Holtzman DM (2010) Biomarkers in translational research of Alzheimer’s disease. Neuropharmacology 59:310–322
Westman E, Cavallin L, Muehlboeck JS, Zhang Y, Mecocci P, Vellas B et al (2011) Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer’s disease. PLoS One 6:e22506
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Menéndez González, M. (2014). Tracking the Progression. In: Atlas of Biomarkers for Alzheimer's Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-07989-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-07989-9_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-07988-2
Online ISBN: 978-3-319-07989-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)